Abstract
Classical Hodgkin lymphoma (cHL) is now recognized as a B-cell-derived lymphoma which is characterized by only about 1% malignant pathognomonic Hodgkin and Reed-Sternberg (HRS) cells and an abundant infiltrate of reactive bystander cells. HRS cells are unique with respect to their lost B-cell-specific gene expression pattern and recurrent genetic lesions. Aberrant activity of Notch signaling, a highly conserved developmental pathway, acts as a negative regulator of the B cell program in HRS cells and thereby contributes to their reprogramming. Another striking feature and the major pathogenetic mechanism in HRS cells is constitutive NF-κB activation. A number of aberrations that contribute to canonical NF-κB activity in HRS cells have been described such as genetic lesions, deregulated receptor signaling and Epstein-Barr virus (EBV) infection. The importance of Notch and NF-κB signaling for cHL pathogenesis, their potential cross-talk and implications for future therapeutic applications are being discussed.
Keywords: Notch, NF-κB, Hodgkin lymphoma, B cell lymphoma, Hodgkin/Reed-Sternberg cells, gene transcription, mutations, immunoprecipitation, inflammatory cells, cytokine, helix-loop-helix proteins, Epstein-Barr virus, Multiple Myeloma, B-chronic lymphocytic leukemia, tumor suppressor gene
Current Molecular Medicine
Title: Notch and NF-κB Signaling Pathways in the Biology of Classical Hodgkin Lymphoma
Volume: 11 Issue: 3
Author(s): R. Schwarzer and F. Jundt
Affiliation:
Keywords: Notch, NF-κB, Hodgkin lymphoma, B cell lymphoma, Hodgkin/Reed-Sternberg cells, gene transcription, mutations, immunoprecipitation, inflammatory cells, cytokine, helix-loop-helix proteins, Epstein-Barr virus, Multiple Myeloma, B-chronic lymphocytic leukemia, tumor suppressor gene
Abstract: Classical Hodgkin lymphoma (cHL) is now recognized as a B-cell-derived lymphoma which is characterized by only about 1% malignant pathognomonic Hodgkin and Reed-Sternberg (HRS) cells and an abundant infiltrate of reactive bystander cells. HRS cells are unique with respect to their lost B-cell-specific gene expression pattern and recurrent genetic lesions. Aberrant activity of Notch signaling, a highly conserved developmental pathway, acts as a negative regulator of the B cell program in HRS cells and thereby contributes to their reprogramming. Another striking feature and the major pathogenetic mechanism in HRS cells is constitutive NF-κB activation. A number of aberrations that contribute to canonical NF-κB activity in HRS cells have been described such as genetic lesions, deregulated receptor signaling and Epstein-Barr virus (EBV) infection. The importance of Notch and NF-κB signaling for cHL pathogenesis, their potential cross-talk and implications for future therapeutic applications are being discussed.
Export Options
About this article
Cite this article as:
Schwarzer R. and Jundt F., Notch and NF-κB Signaling Pathways in the Biology of Classical Hodgkin Lymphoma, Current Molecular Medicine 2011; 11 (3) . https://dx.doi.org/10.2174/156652411795243423
DOI https://dx.doi.org/10.2174/156652411795243423 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews Capturing and Amplifying Impurities from Recombinant Therapeutic Proteins Via Combinatorial Peptide Libraries: A Proteomic Approach
Current Pharmaceutical Biotechnology MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis Microwave Assisted Synthesis of Biorelevant Benzazoles
Current Medicinal Chemistry Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Multiple Myeloma Bone Marrow Niche
Current Pharmaceutical Biotechnology Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs: A Novel Therapeutic Target for Schizophrenia
Current Pharmaceutical Design The Roles of Sox Family Genes in Sarcoma
Current Drug Targets Natural Product Origins of Hsp90 Inhibitors
Current Cancer Drug Targets Hydroxy Cinnamic Acid Derivatives as Partial PPARγ Agonists: In silico Studies, Synthesis and Biological Characterization Against Chronic Myeloid Leukemia Cell Line (K562)
Anti-Cancer Agents in Medicinal Chemistry Anti-MDR Effects of Quercetin and its Nanoemulsion in Multidrug-Resistant Human Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Novel and Emerging Drugs for Acute Myeloid Leukemia: Pharmacology and Therapeutic Activity
Current Medicinal Chemistry The Potential for Genetically Altered Microglia to Influence Glioma Treatment
CNS & Neurological Disorders - Drug Targets Nanotherapeutics in Tumour Microenvironment for Cancer Therapy
Nanoscience & Nanotechnology-Asia Roles of Apoptosis and Cellular Senescence in Cancer and Aging
Current Drug Targets Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology